the Journal of Clinical Oncology
COLUMBUS, Ohio -- A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave.
Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16
Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs.
Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
ROCHESTER, Minn. -- Mayo Clinic researchers have found that certain structural features within breast tissue can indicate a woman's individual cancer risk. The findings appear online today in the Journal of Clinical Oncology.
ANN ARBOR, Mich. -- Latinas who spoke little English were less likely to undergo reconstruction surgery after a mastectomy for breast cancer, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.
Washington, DC -- With the goal of tailoring cancer interventions for the individual, researchers at the Lombardi Comprehensive Cancer Center at Georgetown have published the results of a prospective study that validates the use of a simple blood test to help doctors more reliably assess treatment effectiveness for patients with metastatic breast cancer.
SEATTLE -- It is well known that survivors of breast cancer have a much higher risk of developing a second breast cancer than women in the general population have of developing a first breast cancer.
The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.
BOSTON -- Appropriately selected prostate cancer patients, including older men and men with small, low-risk tumors, may safely defer treatment for many years with no adverse consequences, according to a new study in the Journal of Clinical Oncology (JCO). Led by researchers at Beth Israel Deaconess Medical Center (BIDMC), the study appears online today.
PHILADELPHIA (August 28, 2009) -- Do patients choose where to get their care based on how long it takes to them to get there? Researchers at Fox Chase Cancer Center have recently documented a growing trend in the centralization of cancer surgery -- more patients seeking care at high volume centers, which are generally located in metropolitan areas.
ANN ARBOR, Mich. -- Hospitals that treat more black cancer patients have worse survival rates on average for patients with breast and colon cancer, regardless of race, according to a new study from the University of Michigan Comprehensive Cancer Center.
HOUSTON - A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D.
Investigators at Memorial Sloan-Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.
NEW YORK (July 8, 2009) -- A new finding reveals that African-American patients with breast, ovarian, and prostate cancer tend to die earlier than patients of other races with these cancers, even when they receive identical medical treatment and when socioeconomic factors are controlled for.
